Get real with the BB Warning...they always say the worst possible thing that can happen and that is almost always death. Also Good luck to you, I award you the Crecy Brass Balls award, the first ever awarded for your devotion to Acadia, your fortitude, common sense and hard work for 26 yrs of service to your country. Congrats. I salute you.
If you hedge your long position, do you loose money if there is a Short Squeeze? But if say there is no short squeeze and the stock pulls back can you then make money with your hedged position and then make more money if the stock later runs up ?
That was mostly copy & paste from the yahoo stats page on each stock and using their industry browser page. Just go to any biotech stock and click on " Industry " ...then " Biotechnology ". then " Industry Browser "....You will see many stats that you can click on, eg, Market Cap that will arrange in order higher or lower etc.
Detail folks move around all the time, esp if they feel their present job has limited up side. We need them don't get me wrong, to detail a new CNS drug we need people with experience, so its good for Acadia to have them.
anonymous, Apr 20, 2016 at 2:16 AM
Reps leaving for Acadia
Heard 16 so far, wow
OK this post is by a " guest " who didn't identify themselves, " anonymous ". Has anyone validated this so far and even if it's true, what significance do you see here? Acadia has been hiring sales reps for a while now anyway.
Sounds like they are 3-5 yrs away from any kind of significant P3 studies. But what great science to I.D. cancer stem cells. Talk about going up stream.
Founded in 2008, Stemcentrx combines state-of-the-art research and GMP manufacturing capabilities. This has allowed us to advance from target discovery in our laboratory to treating patients in clinical trials at an accelerated pace. We are investigating many of the largest and most lethal cancers through our proprietary platforms that identify cancer stem cells and discover novel targets,and we engineer and manufacture antibodies and antibody drug conjugates for those targets.
Stemcentrx has five investigational drugs in human clinical trials. As single agents, three have generated objective clinical responses in patients with small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer, and two have recently begun phase I clinical trials. Beyond these five clinical programs, we have a pipeline of additional novel targets to address other major cancer types.
Executives in most large companies, even Federal agency's will come in to work on a weekends off and on, they may not have all the ancillary help they need. So, I am thinking the APPROVAL decision is made on Fri or Sat AM, and simply faxed to ACAD on Sun. This is probably already arranged with the receiving side. Now, I have no clue how the market maker will deal with it from there ?